Dynavax Technologies (DVAX)
(Delayed Data from NSDQ)
$11.27 USD
+0.23 (2.08%)
Updated Aug 14, 2024 04:00 PM ET
After-Market: $11.05 -0.22 (-1.95%) 7:58 PM ET
2-Buy of 5 2
D Value D Growth A Momentum D VGM
Brokerage Reports
Dynavax Technologies Corporation [DVAX]
Reports for Purchase
Showing records 81 - 100 ( 124 total )
Company: Dynavax Technologies Corporation
Industry: Medical - Biomedical and Genetics
LIFE SCIENCES - The Week Ahead in Life Sciences - Upcoming Events for the Week of December 23
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Dynavax Technologies Corporation
Industry: Medical - Biomedical and Genetics
Dropping Coverage Due to Realignment of Research Coverage Since Analyst Departure
Provider: WEDBUSH SECURITIES INC.
Company: Dynavax Technologies Corporation
Industry: Medical - Biomedical and Genetics
LIFE SCIENCES -The Week Ahead in Life Sciences - Upcoming Events for the Week of April 15
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Dynavax Technologies Corporation
Industry: Medical - Biomedical and Genetics
LIFE SCIENCES -The Week Ahead in Life Sciences - Upcoming Events for the Week of April 1
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Dynavax Technologies Corporation
Industry: Medical - Biomedical and Genetics
Earnings Uneventful; Awaiting BLA Filing In May; Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: NASH D
Company: Dynavax Technologies Corporation
Industry: Medical - Biomedical and Genetics
FDA and DVAX Agree to an Expanded Population for HEPLISAV in Pre-BLA Meeting
Provider: WEDBUSH SECURITIES INC.
Analyst: NASH D
Company: Dynavax Technologies Corporation
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of January 22
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Dynavax Technologies Corporation
Industry: Medical - Biomedical and Genetics
Company: Dynavax Technologies Corporation
Industry: Medical - Biomedical and Genetics
LIFE SCIENCES: The Week Ahead in Life Sciences - Upcoming Events for the Week of January 8
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Dynavax Technologies Corporation
Industry: Medical - Biomedical and Genetics
Updating Model Following Milestone Payments from GSK and AZN; Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: NASH D
Company: Dynavax Technologies Corporation
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of November 20
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Dynavax Technologies Corporation
Industry: Medical - Biomedical and Genetics
Company: Dynavax Technologies Corporation
Industry: Medical - Biomedical and Genetics
Completes $64.5 Million Financing; Lowering FV to $5 from $6 on Dilution; Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: NASH D
Company: Dynavax Technologies Corporation
Industry: Medical - Biomedical and Genetics
Reports Top-Line Success in Phase III CKD Study; Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: NASH D
Company: Dynavax Technologies Corporation
Industry: Medical - Biomedical and Genetics
ACIP Vote in Favor of HBV Vaccination of Diabetics Adds to HEPLISAV Market Potential
Provider: WEDBUSH SECURITIES INC.
Analyst: NASH D
Company: Dynavax Technologies Corporation
Industry: Medical - Biomedical and Genetics
GSK Alliance Expands to Include Another TLR Target; Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: NASH D
Company: Dynavax Technologies Corporation
Industry: Medical - Biomedical and Genetics
ACIP Vote on HBV Vaccination for Diabetics Scheduled for October 25; Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: NASH D
Company: Dynavax Technologies Corporation
Industry: Medical - Biomedical and Genetics
Additional Subset Data Demonstrates HEPLISAV Efficacy in Diabetic Patients
Provider: WEDBUSH SECURITIES INC.
Analyst: NASH D
Company: Dynavax Technologies Corporation
Industry: Medical - Biomedical and Genetics
Receives $3M Milestone Payment for Advancing AZD1419 into Clinical Development for Asthma
Provider: WEDBUSH SECURITIES INC.
Analyst: NASH D
Company: Dynavax Technologies Corporation
Industry: Medical - Biomedical and Genetics
HEPLISAV ITT Data Analysis Confirms Strong Efficacy; Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: NASH D